




## Maralixibat

Revised: May 15, 2023.

CASRN: 716313-53-0



## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the use of maralixibat during breastfeeding. Because maralixibat is poorly absorbed orally and 90% bound to plasma proteins, the amount in milk is likely to be low. If maralixibat is required by the mother, it is not a reason to discontinue breastfeeding.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Substance Identification

### Substance Name

Maralixibat

### CAS Registry Number

716313-53-0

### Drug Class

Breast Feeding

Lactation

Milk, Human